MedTrace Logo

A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress

NCT06658535 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-01-28

No results posted yet for this study

Summary

EXTEND is a dose escalation study of NanO2™ in patients with mild respiratory distress who are at risk for mechanical ventilation. The study will establish dosing guidelines for a Phase 2 study.

Conditions

  • Mild Respiratory Distress

Interventions

DRUG

dodecafluoropentane (0.025 mL/kg)

dodecafluoropentane (0.025 mL/kg)

DRUG

dodecafluoropentane (0.032 mL/kg)

dodecafluoropentane (0.032 mL/kg)

DRUG

dodecafluoropentane (0.050 mL/kg)

dodecafluoropentane (0.050 mL/kg)

Sponsors & Collaborators

  • NuvOx LLC

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-13
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06658535 on ClinicalTrials.gov